162 related articles for article (PubMed ID: 26769844)
21. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
Brandt S; Samartzis EP; Zimmermann AK; Fink D; Moch H; Noske A; Dedes KJ
BMC Cancer; 2017 Jan; 17(1):44. PubMed ID: 28073364
[TBL] [Abstract][Full Text] [Related]
22. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
[TBL] [Abstract][Full Text] [Related]
23. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.
Meimei L; Peiling L; Baoxin L; Changmin L; Rujin Z; Chunjie H
Med Oncol; 2011 Mar; 28(1):282-9. PubMed ID: 20054719
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Br J Cancer; 2008 Feb; 98(4):845-51. PubMed ID: 18231102
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor in adnexal masses.
Demirkiran F; Kumbak B; Bese T; Arvas M; Benian A; Aydin S; Uzun H; Sanioglu C; Aydinli K; Kösebay D
Int J Gynaecol Obstet; 2003 Oct; 83(1):53-8. PubMed ID: 14511872
[TBL] [Abstract][Full Text] [Related]
26. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
Manai M; Doghri R; Finetti P; Mrad K; Bouabsa R; Manai M; Birnbaum D; Bertucci F; Charfi L; Driss M
In Vivo; 2020; 34(1):177-184. PubMed ID: 31882477
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo 1H and 31P magnetic resonance spectroscopy as a means for tumor characterization in ovarian cancer patients.
Abramov Y; Carmi S; Anteby SO; Ringel I
Oncol Rep; 2013 Jan; 29(1):321-8. PubMed ID: 23042519
[TBL] [Abstract][Full Text] [Related]
29. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
[TBL] [Abstract][Full Text] [Related]
30. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
Giurgea NL; Pitrop M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.
Polat M; Senol T; Ozkaya E; Ogurlu Pakay G; Cikman MS; Konukcu B; Ozten MA; Karateke A
Clin Transl Oncol; 2016 May; 18(5):457-63. PubMed ID: 26289552
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
33. Cyst fluid metabolites distinguish malignant from benign pancreatic cysts.
Shi J; Yi Z; Jin L; Zhao L; Raskind A; Yeomans L; Nwosu ZC; Simeone DM; Lyssiotis CA; Stringer KA; Kwon RS
Neoplasia; 2021 Nov; 23(11):1078-1088. PubMed ID: 34583246
[TBL] [Abstract][Full Text] [Related]
34. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
Sundfeldt K; Ivarsson K; Rask K; Haeger M; Hedin L; Brännström M
Anticancer Res; 2001; 21(1A):65-70. PubMed ID: 11299791
[TBL] [Abstract][Full Text] [Related]
35. Survivin in ovary tumors.
Plewka D; Jakubiec-Bartnik B; Morek M; Bogunia E; Bienioszek M; Wolski H; Kotrych D; Dziekan K; Seremak-Mrozikiewicz A; Plewka A
Ginekol Pol; 2015 Jul; 86(7):525-30. PubMed ID: 26376531
[TBL] [Abstract][Full Text] [Related]
36. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; Boonstra H; Sweep CG
Cancer; 2001 Jan; 91(2):371-7. PubMed ID: 11180084
[TBL] [Abstract][Full Text] [Related]
38. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.
Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Umemoto M; Sakamoto T; Sato S; Mizunuma H; Smith SK
Br J Cancer; 2003 Jan; 88(2):237-44. PubMed ID: 12610509
[TBL] [Abstract][Full Text] [Related]
40. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]